Effects of endosulfan on the immune function of erythrocytes, and potential protection by testosterone propionate.

While the immunotoxicity of endosulfan has been studied, little is known about its influence on immune function associated with erythrocytes (RBC). The aim of this study was to investigate the possible effects of endosulfan, and any possible mitigation by testosterone propionate (TP), on erythrocyte immune function in a mouse model. To this end, rosette formation [as erythrocyte C3b receptor (E-C3bR) and erythrocyte immune complexes (E-IC)], as well as measures of the erythrocyte C3b receptor rosette-forming enhancing rate (RFER; reflecting immunoenhancing factor activity) and C3b receptor rosette-faulting inhibitory rate (RFIR; reflecting immunosuppressive factor activity) were performed. The effects of RBC on regulating NK cell function or T-cell adherence were also analyzed. Lastly, to begin to assess potential mechanisms by which endosulfan could impact on the measured endpoints, CD35, CD58, and CD59 expression on RBC was evaluated; expression/mRNA levels of complement receptor I-related gene/protein y (Crry) on cells/splenic tissues was also assessed. The data show that E-C3bR rosette ratios decreased, and those of E-IC increased, due to endosulfan treatment. In these hosts, RFER (i.e., immunoenhancing factor in plasma) was decreased, but RFIR (i.e., immunosuppressive factor) was unchanged. There were no clear effects from endosulfan on RBC regulatory function against NK or T-cells. Lastly, Crry mRNA levels in tissues/cells from these mice were significantly decreased; however, CD59 and CD58 expression levels were unaffected. The data also show that TP co-treatment reversed or mitigated effects of endosulfan on each endpoint, in part, by two possible mechanisms; the TP may be increasing the activity of the innate immune enhancing factor, or, an anti-oxidant effect of TP might help to protect membrane structures and increase Crry stability on the RBC.